Jan 08, 2025
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Jan 06, 2025
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Nov 21, 2024
I-Mab to Participate at the Piper Sandler Healthcare Conference
Nov 14, 2024
I-Mab Reports Third Quarter 2024 Results
Nov 06, 2024
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
Oct 30, 2024
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
Oct 28, 2024
I-Mab to Participate at the Truist Securities BioPharma Symposium
Sep 16, 2024
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
Sep 10, 2024
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
Aug 28, 2024
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
Aug 26, 2024
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 14, 2024
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
Aug 07, 2024
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
Jun 06, 2024
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
Apr 30, 2024
I-MAB Filed 2023 Annual Report on Form 20-F
Apr 05, 2024
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Nov 14, 2019
I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China
Oct 04, 2019
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
Sep 23, 2019
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
Sep 12, 2019
I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S.